Federal Court Dismisses Whistleblower Patent Fraud Lawsuit Against Valeant and Salix Over Ulcerative Colitis Drug Apriso
Key Insights
A federal judge dismissed a seven-year False Claims Act lawsuit against Valeant Pharmaceuticals and Salix Pharmaceuticals alleging fraudulent patent practices for ulcerative colitis (search) drug Apriso.
Whistleblower Zachary Silbersher claimed the companies fraudulently obtained patents, excluded generic competitors, and overbilled Medicare for prescriptions.
The dismissal was without prejudice, allowing the plaintiff to amend and refile claims with more specific allegations against each defendant.
A federal judge has dismissed a long-running whistleblower lawsuit alleging patent fraud and Medicare overbilling against Valeant Pharmaceuticals International Inc. (search) and Salix Pharmaceuticals Inc. related to the ulcerative colitis (search) medication Apriso. The dismissal, while significant for the pharmaceutical companies, allows the plaintiff to potentially refile with amended claims.
Court Ruling Details
Judge James Donato of the US District Court for the Northern District of California issued a Tuesday order dismissing the False Claims Act suit without prejudice. The judge determined that whistleblower Zachary Silbersher failed to allege fraud against each defendant with the required legal particularity necessary to sustain the claims.
The seven-year legal battle centered on allegations that the pharmaceutical companies engaged in fraudulent patent practices that ultimately harmed government healthcare programs and patients seeking treatment for ulcerative colitis (search).
Allegations Against Pharmaceutical Companies
Silbersher's lawsuit alleged a multi-faceted scheme involving the ulcerative colitis (search) drug Apriso. According to the whistleblower's claims, Valeant, Salix, and other defendants fraudulently obtained patent protection for the medication, creating barriers that wrongly excluded generic competitors from the market.
The lawsuit further alleged that this patent manipulation led to overbilling of Medicare for Apriso prescriptions, potentially costing the government healthcare program significant funds while limiting patient access to more affordable generic alternatives.
Legal Implications and Next Steps
The dismissal without prejudice represents a procedural victory for Valeant and Salix, as it removes the immediate legal threat while preserving the companies' ability to defend against potential future amended claims. This type of dismissal allows the plaintiff to revise and refile the lawsuit with more detailed allegations that meet the court's standards for specificity.
For pharmaceutical companies facing similar patent-related litigation, the ruling underscores the importance of detailed pleading requirements in False Claims Act cases, particularly when alleging complex fraud schemes involving multiple corporate defendants.
The case highlights ongoing scrutiny of pharmaceutical patent practices and their impact on healthcare costs, particularly regarding government programs like Medicare that serve vulnerable patient populations requiring specialized treatments for chronic conditions like ulcerative colitis (search).